Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.77%
1,097.81
-8.55
-0.77%
—1,106.361,105.681,109.291,096.52——
SIXC
Communications
SIXC
Communications
SIXC
+0.29%
612.03
+1.74
+0.29%
—610.29610.29616.60610.29——
SIXE
Energy
SIXE
Energy
SIXE
+0.76%
1,220.43
+9.21
+0.76%
—1,211.221,211.011,222.361,208.50——
SIXI
Industrials
SIXI
Industrials
SIXI
+0.50%
1,759.52
+8.81
+0.50%
—1,750.711,753.101,762.131,743.30——
SIXM
Financials
SIXM
Financials
SIXM
+0.54%
631.54
+3.37
+0.54%
—628.17629.38634.09629.38——
SIXR
Staples
SIXR
Staples
SIXR
+0.30%
857.16
+2.59
+0.30%
—854.57855.71860.09855.45——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.67%
215.41
-1.46
-0.67%
—216.87216.87217.79215.29——
SIXT
Technology
SIXT
Technology
SIXT
+1.47%
3,614.15
+52.21
+1.47%
—3,561.943,571.443,628.583,562.15——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.55%
908.30
+4.99
+0.55%
—903.31903.26908.38901.18——
SIXV
Health care
SIXV
Health care
SIXV
-0.08%
1,480.40
-1.14
-0.08%
—1,481.541,482.481,488.461,474.18——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.07%
2,398.37
-1.58
-0.07%
—2,399.952,404.452,418.812,396.04——
WOCKPHARMA:NSE
Wockhardt Ltd
₹1,546.00
-1.22%
(-19.10) 1D
May 14, 3:30:01 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for WOCKPHARMA...
Open
₹1,573.00
High
₹1,610.00
Low
₹1,505.00
Mkt. cap
251.21B
Avg. vol.
2.02M
Volume
1.27M
P/E ratio
118.02
52-wk high
₹1,868.80
52-wk low
₹1,086.70
EPS
₹13.10
Shares outstanding
110.69M
No. of employees
2K
News stories
From sources across the web
Profile
Wockhardt is an Indian pharmaceutical and biotechnology company headquartered in Mumbai, India. It produces formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients. The company has manufacturing plants in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France. Wikipedia
About Wockhardt Ltd
CEOMurtaza Khorakiwala
Employees2.3K
Founded1967
Headquarters-
SectorPharmaceutical industry
Websitewockhardt.com
Last report
May 4, 2026
Fiscal Period
Q4 2026
EPS / Est. (INR)
- / -
Revenue / Est. (INR)
10.10B / -
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
7.38B
7.82B
8.88B
10.10B
Cost of goods sold
2.64B
2.33B
3.17B
3.18B
Cost of revenue
2.64B
2.33B
3.17B
3.18B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.71B
1.86B
1.81B
1.87B
Operating expense
4.29B
4.42B
4.63B
5.04B
Total operating expenses
6.93B
6.75B
7.80B
8.22B
Operating income
450.00M
1.07B
1.08B
1.88B
Other non operating income
200.00M
210.00M
250.00M
-
EBT including unusual items
-1.09B
910.00M
670.00M
1.89B
EBT excluding unusual items
-120.00M
910.00M
770.00M
1.67B
Income tax expense
-10.00M
90.00M
60.00M
250.00M
Effective tax rate
0.92%
9.89%
8.96%
13.23%
Other operating expenses
2.02B
2.03B
2.17B
2.64B
Net income
-900.00M
780.00M
590.00M
1.66B
Net profit margin
-12.20%
9.97%
6.64%
16.44%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-480.00M
-550.00M
-600.00M
-500.00M
Net interest expenses
-480.00M
-550.00M
-600.00M
-500.00M
Depreciation and amortization charges
560.00M
530.00M
650.00M
530.00M
EBITDA
842.50M
1.62B
1.47B
2.45B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer